Clinical trials: Systemic Lupus Erythematosus
Systemic Lupus Erythematosus, Depression
LUPUS Brain: tACS to Target the Neurophysiology of Depression, Cognitive Deficits, and Pain in Patients With SLE
The purpose of this study is to investigate the effects of a type of non-invasive transcranial alternating current stimulation (tACS) on patients diagnosed with systemic lupus erythematosus (SLE) who are experiencing depression.
- Trial name
- NCT04141046
- Testing
- XCSITE100 Stimulator - Individualized theta-tACS, XCSITE100 Stimulator - Individualized alpha-tACS
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Lupus Nephritis
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult (18-75 years) subjects with active LN suitable for systemic therapy.
- Trial name
- NCT07393451
- Testing
- SIM0278 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
Systemic Lupus Erythematosus (SLE)
It is an Observational Study That Compare Prognosis of Typical and Atypical Systemic Lupus Erythematosus Presentation
Atypical presentations of SLE including unusual initial symptoms, predominant organ involvement, late-onset disease and ANA-negative remain poorly characterized.
- Trial name
- NCT07350772
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Sohag University
Systemic Lupus Erythematosus (SLE)
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will evaluate how well elsubrutinib and upadacitinib given alone or as the ABBV-599 combination…
- Trial name
- NCT04451772
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 87 sites in United States, Argentina and 16 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Systememic Lupus Erythematosus, Systemic Sclerosis (SSc)
Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies
Systemic autoimmune diseases associated with type I interferon (IFN-I) dysregulation, such as systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type…
- Conditions
- Systememic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathies, Connective Tissue Diseases
- Trial name
- SAFRAN (NCT07837986)
- Testing
- biological samples
- Where
- 3 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Systemic Lupus Erythematosus
Aspirin Resistance in Systemic Lupus Erythematosus (SLE)
This study examine whether patients with lupus respond to aspirin , and if not, if that is related to inflammation. We examine the ability of aspirin to inhibit the production of thromboxane in patients with lupus and controls…
- Trial name
- NCT00731302
- Testing
- aspirin and meloxicam
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Systemic Lupus Erythematosus
Anti-infection of Low-does IL-2 in SLE
The objective of this clinical study is to evaluate the potential effect of anti-infection of low-does IL-2 in patients with SLE.
- Trial name
- NCT02932137
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Systemic Lupus Erythematosus
HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms
The purpose of this study is to assess the efficacy, feasibility, and acceptability of Virtual Reiki therapy as a complementary treatment for patients with systemic lupus erythematosus (SLE).
- Trial name
- HEAL-SLE (NCT07203157)
- Testing
- Virtual Reiki Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Myasthenia Gravis, Systemic Lupus Erythematosus
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
The aim of this pilot study is to investigate the application of proteasome inhibitor Bortezomib (Velcade®, approved for therapy of multiple myeloma) in patients with therapy-refractory antibody-mediated autoimmune diseases.
- Conditions
- Myasthenia Gravis, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- TAVAB (NCT02102594)
- Testing
- Bortezomib
- Where
- 2 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Charite University, Berlin, Germany
Inflammatory Disease, Crohn Disease
Monitoring of Inflammatory Conditions
People with inflammatory diseases treated with immune-suppressing medication are recommended to have regular blood-tests to monitor for potential side-effects of this treatment on their blood count, liver and kidneys.
- Conditions
- Inflammatory Disease, Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis
- Trial name
- NCT05458531
- Testing
- Questionnaire, Semi-structured interview
- Where
- United Kingdom
- Volunteers
- 664 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
SARS-CoV-2, Systemic Lupus Erythematosus
Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients…
- Conditions
- SARS-CoV-2, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's Syndrome
- Trial name
- COVCALL (NCT04345159)
- Testing
- Questionnaire by phone call
- Where
- France
- Volunteers
- 572 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Lupus Erythematosus, Systemic
Prognostic Factors for Fatigue in Patients With Systemic Lupus Erythematosus
Introduction: Fatigue is a well-established symptom in systemic lupus erythematosus. Depression and anxiety can develop at different stages of systemic lupus erythematosus and their severity can range from mild symptoms to more…
- Trial name
- NCT07123220
- Where
- Spain
- Volunteers
- 884 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Lupus Nephritis
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of CNTO 136 administered intravenously in patients with active, International Society of Nephrology/Renal Pathology Society Class III and IV Lupus Nephritis (LN).
- Trial name
- NCT01273389
- Testing
- CNTO 136
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Janssen Research & Development, LLC
Autoimmune Diseases
Deciphering the Genetic Architecture of Autoimmune Diseases
Background: Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause these diseases have been well studied in people with European and Asian ancestors.
- Trial name
- NCT06948110
- Where
- 2 sites in United States, Peru
- Volunteers
- 300 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Lupus Erythematosus, Systemic
Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial)
The trial is designed to evaluate prevalence of fragility fracture, their impact on quality of life of SLE patients and disease or treatment variables such as steroids dosage or use of specific drugs like hydroxychloroquine…
- Trial name
- FRAIL (NCT05590390)
- Testing
- DXA, serum sample, PROs
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Systemic Lupus Erythematosus
Cyclophosphamide in Lupus Nephritis
Cyclophosphamide is widely used in the treatment of cancer and autoimmune diseases such as lupus nephritis. However, there is considerable variability in the response to cyclophosphamide treatment.
- Trial name
- NCT00441220
- Where
- 3 sites in New Zealand
- Volunteers
- 60 people
- Sponsor
- University of Auckland, New Zealand
SLE (Systemic Lupus)
National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia
SLE disease in Saudi Arabia is yet not well defined especially in a population with high consanguinity and high inbreeding coefficient . Up until now, there has been no prospective cohort study for SLE patients in Saudi Arabia.
- Trial name
- NCT04604990
- Where
- Saudi Arabia
- Volunteers
- 1,000 people
- Sponsor
- King Saud University
Systemic Lupus Erythematosus
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
The purpose of this study was to explore the clinical and immunological efficacy of Telitacicept and low dose IL-2 on systemic lupus erythematosus.
- Trial name
- NCT05339217
- Testing
- Telitacicept, Interleukin-2
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Liu Tian
Systemic Lupus Erythematosus
Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus
To assess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China.
- Trial name
- NCT06297408
- Testing
- Relma-cel
- Volunteers
- 24 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Systemic Lupus Erythematosus
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
- Trial name
- NCT05306574
- Testing
- Telitacicept
- Where
- 78 sites in United States, Argentina and 13 more
- Volunteers
- 91 people
- Sponsor
- Vor Biopharma